We are live on ! Find out more
RCUS icon

Arcus Biosciences
RCUS

181 hedge funds and large institutions have $1.11B invested in Arcus Biosciences in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 59 increasing their positions, 65 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more call options, than puts

Call options by funds: $26.7M | Put options by funds: $23.2M

13% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 23

10% more capital invested

Capital invested by funds: $1.01B → $1.11B (+$98.2M)

1% more funds holding

Funds holding: 179 → 181 (+2)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

9% less repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 65

1.11% less ownership

Funds ownership: 75.93% → 74.82% (-1.1%)

Holders
181
Holders Change
+2
Holders Change %
+1.12%
% of All Funds
2.84%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
26
Increased
59
Reduced
65
Closed
23
Calls
$26.7M
Puts
$23.2M
Net Calls
+$3.5M
Net Calls Change
+$742K

Top Buyers

1
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$35.5M
2
Ameriprise
Ameriprise
Minnesota
+$24.4M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$23.8M
4
LGM
Logos Global Management
California
+$14.3M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$13.5M

Top Sellers

1
State Street
State Street
Massachusetts
-$22M
2
Citadel Advisors
Citadel Advisors
Florida
-$19.6M
3
Bank of America
Bank of America
North Carolina
-$18.3M
4
BlackRock
BlackRock
New York
-$12.7M
5
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$12.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$8.87M +$287K +15,050 +4%
ECM
27
ExodusPoint Capital Management
New York
$8.87M +$176K +9,258 +2%
Macquarie Group
28
Macquarie Group
Australia
$7.7M – – –
Susquehanna International Group
29
Susquehanna International Group
Pennsylvania
$7.67M +$2.2M +115,352 +44%
UBS AM
30
UBS AM
Illinois
$7.5M – – –
SAM
31
Sectoral Asset Management
Quebec, Canada
$7.2M +$1.16M +60,844 +21%
Principal Financial Group
32
Principal Financial Group
Iowa
$6.66M +$64.6K +3,390 +1%
GIM
33
Granahan Investment Management
Massachusetts
$6.39M -$4.99M -261,912 -45%
Rafferty Asset Management
34
Rafferty Asset Management
New York
$6.1M -$2.11M -110,880 -27%
Jane Street
35
Jane Street
New York
$5.86M +$4.81M +252,847 +711%
T. Rowe Price Associates
36
T. Rowe Price Associates
Maryland
$5.72M +$39.8K +2,090 +0.7%
IC
37
Ikarian Capital
Texas
$5.69M +$952K +50,000 +22%
Squarepoint
38
Squarepoint
New York
$5.57M +$3.56M +186,862 +213%
Invesco
39
Invesco
Georgia
$5.06M -$647K -33,954 -12%
WP
40
Woodline Partners
California
$5.04M +$4.72M +248,000 New
GGHC
41
Gilder Gagnon Howe & Co
New York
$4.9M +$249K +13,078 +6%
EAM
42
Eventide Asset Management
Massachusetts
$4.87M – – –
PIM
43
Platinum Investment Management
Australia
$4.72M – – –
DCM
44
DAFNA Capital Management
California
$4.58M +$962K +50,500 +29%
BFM
45
Boothbay Fund Management
New York
$3.94M -$461K -24,201 -11%
Bank of America
46
Bank of America
North Carolina
$3.82M -$18.3M -961,197 -84%
Nordea Investment Management
47
Nordea Investment Management
Sweden
$3.79M -$1.44M -75,423 -29%
SSA
48
Schonfeld Strategic Advisors
New York
$3.72M -$2.11M -110,786 -38%
Barclays
49
Barclays
United Kingdom
$3.37M +$69.3K +3,642 +2%
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$3.37M -$5.62K -295 -0.2%
1
2
3 4 5

RCUS Hedge Fund Activity: Q2 2023 in Review

181 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q2 2023, worth a combined $1.11B — up 9.7% from $1.01B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new RCUS positions and 23 closed out — a net gain of 3 holders — while 59 added to existing stakes and 65 trimmed.

The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $35.5M. The largest seller was State Street, cutting an estimated $22M.

  • 181 institutional investors held Arcus Biosciences (RCUS) as of Q2 2023, up from 179 in Q1 2023.
  • Funds reported $1.11B of Arcus Biosciences stock for Q2 2023, up 9.7% quarter-over-quarter.
  • 26 funds opened new Arcus Biosciences positions in Q2 2023 and 23 closed out, a net change of +3 holders.
  • The largest Arcus Biosciences buyer in Q2 2023 was Balyasny Asset Management, an estimated $35.5M added.
  • The largest Arcus Biosciences seller in Q2 2023 was State Street, an estimated $22M sold.

Based on aggregated 13F filings for Q2 2023.